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Abstract. Human brain mapping has become one of the most exciting contemporary research areas, with major
breakthroughs expected in the coming decades. Modern brain imaging techniques have allowed neuroscientists
to gather a wealth of anatomic and functional information about the brain. Among these techniques, by virtue of
its rich optical absorption contrast, high spatial and temporal resolutions, and deep penetration, photoacoustic
tomography (PAT) has attracted more and more attention, and is playing an increasingly important role in brain
studies. In particular, PAT complements other brain imaging modalities by providing high-resolution functional
and metabolic imaging. More importantly, PAT’s unique scalability enables scrutinizing the brain at both micro-
scopic and macroscopic scales, using the same imaging contrast. In this review, we present the state-of-the-art
PAT techniques for brain imaging, summarize representative neuroscience applications, outline the technical
challenges in translating PAT to human brain imaging, and envision potential technological deliverables. © The
Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part
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1 Introduction
Although scientists have been avidly discovering the secrets of
the brain, the knowledge accumulated so far still falls far short of
a comprehensive understanding.1,2 Due to modern biomedical
technologies, especially imaging technologies, our understand-
ing of the brain has advanced over the last few decades at an
accelerating speed.3,4 Looking back, the history of neuroscience
is also a history of applying new imaging technologies to
look at the brain in a more informative way: finer resolution,
higher speed, deeper penetration, and new functionality. Given
its impact, brain research is, understandably, the most attrac-
tive and rewarding application of newly developed imaging
technologies.
So far, a number of imaging technologies have been applied
in neuroscience studies.3 Among them, two-photon microscopy
and functional magnetic resonance imaging (fMRI) are the
major tools of choice. At the microscopic scale, two-photon
microscopy allows detailed and direct examination of neuroac-
tivities in small animal models, such as action potential firing,
the release of signaling molecules, and extra-cellular ion pump-
ing.5 At the macroscopic scale, fMRI has been extensively used
to map human brain activities, allowing indirect coarse-grained
localization of complex cognitive functions, such as language,
emotion, decision-making, learning, and memory.6 Collectively,
modern brain imaging technologies have provided a solid foun-
dation and the strong springboard needed for the next advance of
neuroscience.
Naturally, it is necessary to relate two-photon microscopic
findings on small animals to the macroscopic fMRI observations
on humans.3 However, correlation between the two imaging
scales is truly an engineering challenge, because two-photon
microscopy cannot provide penetration into human brain
through an intact skull,7 and fMRI cannot achieve spatial
resolution at the single cell level.3 Beyond the resolution
discrepancy, an even more fundamental constraint is the dra-
matically different signal contrasts of the two modalities. In par-
ticular, the relationship between fMRI signals and underlying
brain activities remains unclear.3 Therefore, there is a gap
between the macroscopic activity patterns available in humans
and the microscopic activity details available in small animal
models. Bridging this gap provides a unique opportunity for
photoacoustic tomography (PAT), a hybrid imaging modality
that can readily encompass both the microscopic and macro-
scopic worlds with the same contrast mechanism.8–10
Briefly, PAT is based on the photoacoustic (PA) effect, which
starts with optical absorption by tissue molecules and ends with
ultrasonic emission through thermoelastic expansion. The com-
bination of optical excitation with ultrasonic detection immedi-
ately offers PAT two advantages: (1) the resultant PA signal is
sensitive to the rich optical absorption contrast of the biological
tissue, which provides the functional and metabolic imaging
capabilities and (2) the acoustic waves are not as sensitive
to scattering as light, which leads to high spatial resolution
in deep tissue. Detailed reviews of PAT technologies can be
found in several recent publications.9,11,12
In this review, we will present the state-of-the-art PAT tech-
nology, focusing on its multiscale, functional, and metabolic
brain imaging capabilities. Then, we will summarize the repre-
sentative applications of PAT in neuroscience studies. Further
improvements in PAT of the brain, especially for humans,
will be discussed. The potential paths toward clinical brain
imaging by PAT will be outlined, and likely achievements in
the coming years will be envisioned.*Address all correspondence to: Lihong V. Wang, E-mail: lhwang@wustl.edu
Neurophotonics 011003-1 Jul–Sep 2014 • Vol. 1(1)
Neurophotonics 1(1), 011003 (Jul–Sep 2014) REVIEW
Downloaded From: http://neurophotonics.spiedigitallibrary.org/ on 06/17/2016 Terms of Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
2 Multiscale PAT of the Brain
The brain is a multiscale, multilayer, and multicompartment
system for robust behaviors. Although a human brain has an
average volume of ∼1450 cm3, single neurons and glial cells,
the building blocks of the brain, are on the scale of microme-
ters.13 Although the total human cortex is about 3-mm thick,
the thickness of each of the six cortical layers is on the scale of
a few hundreds of micrometers. Through different implementa-
tions, PAT is capable of imaging the brain at different length
scales. The spatial resolution of PAT can be tuned in both
the optical and acoustic domains, while the imaging depth
changes accordingly.9 The optimum tradeoff between spatial
resolution and imaging depth depends on the specific applica-
tion. As a rule of thumb, the ratio of the imaging depth to the
spatial resolution of different PAT implementations is ∼200,
qualifying PAT as a high-resolution imaging modality across
a wide length scale range.9
Although different classifications of PAT exist, we classify it
based on the imaging depth in units of the optical transport mean
free path (TMFP, ∼1 mm in muscle and ∼0.6 mm in the brain).7
This classification emphasizes PAT’s tolerance of optical scat-
tering, a primary limiting factor in high-resolution optical imag-
ing. Based on the targeted imaging depth, PAT falls into three
groups: (quasi)ballistic PAT, with an imaging depth smaller
than one TMFP (typically <0.6 mm); quasidiffusive PAT, with
an imaging depth of 1 to 10 TMFPs (typically 0.6 to 6 mm); and
diffusive PAT, with an imaging depth larger than 10 TMFPs
(typically >6 mm). For each depth regime, we will discuss
the relevant PAT technologies, their imaging characteristics
and representative applications in neuroscience.
2.1 (Quasi)ballistic PA Imaging of the Brain
Ballistic PAT targets the imaging depth of one TMFP, which is
similar to the thickness of a mouse cortex. Ideally, the term “bal-
listic imaging” is based on unscattered photons. In reality, more-
scattered quasiballistic photons are also used to increase the
signal strength. For brevity, subsequent use of “ballistic” in this
review also refers to “quasiballistic” unless otherwise noted.
In the ballistic regime, the representative PAT implementation
is optical-resolution photoacoustic microscopy (OR-PAM).14,15
As shown in Fig. 1(a), in OR-PAM, the excitation laser beam
is tightly focused by an objective lens to an optical-diffraction-
limited spot, and a single-element ultrasonic transducer detects
the resultant PA signals. Although the ultrasonic transducer is
often confocally aligned with the objective lens for optimum
detection sensitivity, the optical focusing is generally more
than 10 times tighter by diameter than the acoustic focusing,
and thus the lateral resolution of OR-PAM is determined by
the optical focusing. The axial resolution of OR-PAM is deter-
mined by the detection bandwidth of the ultrasonic transducer,
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Fig. 1 Multiscale label-free photoacoustic (PA) brain imaging. (a) Optical-resolution photoacoustic
microscopy (OR-PAM) of mouse cortical vasculature with the scalp removed but the skull intact.16
The optical lateral resolution of ∼3 μm allows imaging the cortical blood vessel on the capillary level
with a penetration depth of <1 mm. UT, ultrasonic transducer. (b) Acoustic-resolution PAM (AR-
PAM) of cortical vasculature in a living adult mouse with both the scalp and skull intact.17 A penetration
depth of ∼3 mm can be achieved with an acoustic-diffraction-limited resolution of ∼70 μm. (c) Circular-
view photoacoustic computed tomography (PACT) of the cortical vasculature in a living adult rat with both
the scalp and skull intact.18With a 3.5 MHz ultrasonic transducer, a penetration depth of 8 mm can be
achieved, with an in-plane resolution of 0.2 mm. (d) Circular-view thermoacoustic tomography (TAT) of a
monkey brain with the scalp and skull intact.19 With microwave excitation, brain structures that are 3-cm
deep in the head (e.g., the corpus callosum) can be clearly imaged with an in-plane resolution of 4 mm.
Sale bars: 1 mm for (a–c) and 1 cm for (d). With laser excitation, hemoglobin in red blood cells provided
the image contrast for (a)–(c). With microwave excitation, TAT imaged the water content in the brain in
(d). Adapted with permission from Refs. 16, 17, 18, and 19.
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which is chosen to match the acoustic path length due to
frequency-dependent acoustic attenuation. By adjusting the
numerical aperture (NA) of the optical objective lens and/or
the excitation wavelength, OR-PAM has achieved lateral reso-
lutions ranging from 220 nm to 5 μm, with imaging depths rang-
ing from 100 μm to 1.2 mm in chicken breast tissue.11 Our
experimental results show that the penetration depth of OR-
PAM at 570 nm in the mouse brain is ∼0.6 mm with skull intact
and 1.0 mm without skull. The penetration depth can be
improved by using near-infrared excitation at 1064 nm.
Capitalizing on its high spatial resolution, OR-PAM can
provide high-quality mouse cortical vasculature images using
hemoglobin in red blood cells (RBCs) as the endogenous con-
trast.16 Due to the limited penetration depth of OR-PAM, the
scalp of the mouse has to be removed, but the skull is kept intact.
As shown in Fig. 1(a), cortical vasculature of a mouse brain is
well resolved, down to capillaries.16 Therefore, OR-PAM is well
suited for monitoring cortical hemodynamics as surrogates of
the underlying neural activities.
OR-PAM is also suitable for single neuron imaging, using
exogenous or endogenous contrast. For example, densely
packed neuron cells cultured in medium were imaged by
OR-PAM, assisted by immunochemistry staining of Tuj1
[Figs. 2(a) and 2(b)]. The single neuron cell body, dendrites,
and nucleus can be clearly resolved. Alternatively, OR-PAM
can image neurons by using lipids in the myelin as the endog-
enous imaging contrast. As shown in Fig. 2(c), the wavy fibrous
structure in the OR-PAM image of an unsectioned sciatic nerve
is caused by the bundles of myelin-coated axons that form
the nerve fascicles.20 The bright round structures may be
surrounding fat cells. Therefore, by using OR-PAM with
appropriate contrast agents, it is possible to study single neuron
activities, such as action potential propagation, neural transmit-
ter release, and communications between synapses.
2.2 Quasidiffusive PAT of the Brain
Quasidiffusive PAT targets imaging depths in the quasidiffusive
regime, which is more than one TMFP but less than 10 TMFPs.
This imaging depth is ideal for small animal whole-brain imag-
ing, since the entire mouse brain is about 5- to 7-mm thick.
The core technologies involved in quasidiffusive PAT may
not be fundamentally different from those used in ballistic or
diffusive PAT, but modifications are needed to optimize the
imaging performance for intermediate scale brain imaging.17
The representative quasidiffusive PAT implementation is
acoustic-resolution photoacoustic microscopy (AR-PAM).21,22
With regard to the spatial resolution, AR-PAM can also be clas-
sified as a microscopic modality, because it can achieve a spatial
resolution better than the resolving capability of the naked eye
(∼50 μm) when a high frequency ultrasonic transducer (e.g.,
50 MHz) is used.21 Here, we consider AR-PAM as a “quasidif-
fusive” modality because it can break the optical diffusion limit.
Similar to OR-PAM, AR-PAM focuses the laser pulses to an
area in tissue that coincides with the focal spot of a wideband
ultrasonic detector [Fig. 1(b)]. However, unlike OR-PAM, the
laser focus in AR-PAM is intentionally tuned wider than the
ultrasonic focal spot, so that the entire volume of the ultrasonic
focal zone is adequately illuminated. In this case, the resolution
does not closely depend on the tissue’s optical scattering char-
acteristics, because it is not the optical focusing ability but the
ultrasonic focusing that determines the resolution at depths
within a few TMFPs. By adjusting the central frequency of
the ultrasonic transducer and/or the NA of the acoustic focusing
lens, the lateral resolution of AR-PAM can be scaled. As in OR-
PAM, the axial resolution of AR-PAM is determined by the
bandwidth of the ultrasonic transducer.
Considering the acoustic properties of mouse scalp and skull,
Stein et al. specially engineered AR-PAM for noninvasive im-
aging of the major mouse cortical vessels with both the scalp
and skull intact [Fig. 1(b)]. By using a focused ultrasonic trans-
ducer with a central frequency of 20 MHz and bandwidth of
90%, AR-PAM has achieved a lateral resolution of 70 μm
and an axial resolution of 27 μm, with an imaging depth of
more than 3.6 mm in the mouse brain.17
2.3 Diffusive PAT of the Brain
In the diffusive regime, photoacoustic computed tomography
(PACT) is the major implementation for brain imaging.18 In con-
trast to OR-PAM/AR-PAM, where a focused single-element
transducer is transversely scanned, PACT utilizes a state-of-
the-art transducer array to simultaneously detect the PA
waves from the entire region of interest excited by an expanded
laser beam [Fig. 1(c)]. Then, an inverse algorithm—essentially a
method for sophisticated triangulation of PA sources from the
detected time-resolved acoustic signals—is used to reconstruct
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Fig. 2 PAmicroscopy of neurons. (a) OR-PAM of embryoid body-derived neurons, where neurofilaments
were stained with anti-neurofilament/HRP-secondary antibody/DAB. (b) The close-up image of the
dashed box region in (a) clearly shows the nucleus and detritus of a single neuron cell. (c) OR-PAM
image of an unsectioned label-free sciatic nerve at 1210 nm.20 The lipids in myelin provided the
image contrast. The wavy fibrous structure in the image is caused by the bundles of myelin-coated
axons that form the nerve fascicles. The bright round structures may be surrounding fat cells.
Adapted with permission from Ref. 20.
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a high-resolution PACT image. Although a one-dimensional
(1-D) array can provide one-dimensional (2-D) PA images,23
a 2-D array can perform three-dimensional PA imaging without
extra mechanical scanning.24–26
Depending on the anatomy of the organ of interest, the trans-
ducer array in PACT can be constructed with different shapes,
e.g., a circle23,27 or a plane25 for the brain, a hemisphere for
the breast,28 and an arch for small animal trunks.29,30 As most
ultrasonic arrays are 1-D, the axial and lateral resolutions of
a PACT system are primarily determined by the bandwidth of
the ultrasonic transducer and image reconstruction,31 whereas
the elevational resolution usually comes from cylindrical acous-
tic focusing.9
PACT is ideal for deep brain imaging. The deep penetration
of PACT is achieved by the combination of near-infrared (NIR)
optical excitation and low frequency ultrasonic detection. A
PACT system adapted from a clinical linear-array ultrasound
machine operating at 4 to 8 MHz has demonstrated an imaging
depth of 7 cm in tissue phantom, with a lateral resolution of
720 μm and an axial resolution of 400 μm.9 With the deep pen-
etration, PACT has been extensively used for noninvasive brain
imaging. In fact, the very first in vivo demonstration of PAT
technology was to visualize the 3-D structures of a rat brain
with both scalp and skull intact18 [Fig. 1(c)]. Interior brain struc-
tures ∼8 mm beneath the scalp surface were clearly imaged.18
In addition to small animal brains, PACT has successfully
imaged rhesus monkey brains through a skull thickness of
∼2 mm.32 A 1 MHz (low frequency) ultrasonic transducer
was used to receive PAwaves that survived the acoustic attenu-
ation and distortion by the relatively thick scalp and skull.
To further extend the imaging depth, radio frequency
excitation can be used instead of laser excitation, a variant tech-
nology called thermoacoustic tomography [Fig. 1(d)]. Brain
features ∼3-cm deep in the monkey head were imaged with
a resolution of 4 mm.19 With this resolution and imaging
depth, noninvasive human braining imaging is on the near
horizon.
2.4 Transitions Among Multiscale PAT
Implementations
Transitions among PAT implementations at different length
scales merit a further discussion. As noted above, in PAT, the
transition from ballistic through quasidiffusive to diffusive
brain imaging is rather flexible and continuous, with significant
overlap among various implementations.7
From a technology standpoint, PACT can be adapted for qua-
sidiffusive imaging by using ultrasonic detectors with a higher
central frequency and wider bandwidth.25,33 Likewise, AR-PAM
can be adjusted for diffusive imaging by using low frequency
ultrasonic detectors. For example, in AR-PAM, reducing the
center frequency to 5 MHz extends the imaging depth to
4 cm and relaxes the lateral resolution to 560 μm, an implemen-
tation called photoacoustic macroscopy (PAMac).34 Further, as
optical focusing becomes gradually inefficient with increasing
imaging depth, OR-PAM eventually transitions into AR-PAM.35
In addition, there are hybrid implementations.36,37 In a
recently developed optical-resolution PACT system, the field
of view is simultaneously excited by an array of 1800 diffrac-
tion-limited optical foci, and the resultant PAwaves are detected
by a 512-element transducer array.36 The parallel excitation and
detection enable fast wide-field mouse brain imaging, while
the imaging depth is restricted to one TMFP.
Overall, the flexible transitions among PAT implementations
have provided a practical solution for multiscale brain imaging
with the same imaging contrast.
3 Functional PAT of the Brain in
Action and at Rest
Brain is the functional center of the human body, exerting cen-
tralized control over the other organs. Functional brain imaging
is crucial for neuroscience studies, relating observable brain
behaviors to underlying neural activities. Brain functions as a
multilevel system, from neuron-to-neuron communications to
column-to-column interconnections. PAT is promising for multi-
level brain functional imaging. So far, PAT has been used in
a number of brain studies and provided valuable information
about brain oxygenation, brain metabolism, resting state brain
connectivity, and brain responses to various physiological and
pathological challenges. Here, we will present representative
PAT brain studies and elaborate on the associated imaging
technologies.
3.1 PAT of Brain Oxygenation
Oxygenation is an important indicator of the brain’s functional
status. When neuronal activity increases, there is an increased
demand for oxygen, which triggers an increase in blood flow
to the activated region. Generally, the blood flow increases
not just to a level where oxygen demand is met, but to a
level of overcompensation for the increased demand. Thus
blood oxygenation actually increases following neural activa-
tion. The change in local blood oxygenation reflects the level
of neural activity, which forms the principle of the blood oxy-
genation level dependent (BOLD) signals in fMRI.6 However,
since the BOLD signal is sensitive only to the paramagnetic
deoxy-hemoglobin (HbR), fMRI cannot distinguish between
increased blood oxygenation and decreased blood perfusion
(i.e., volumetric concentration of hemoglobin in the brain tis-
sue). Therefore, to avoid this ambiguity, fMRI needs additional
information about the change in volumetric concentration of
hemoglobin in the brain tissue. In contrast, PAT is sensitive
to both oxy-hemoglobin (HbO2) and HbR, and thus can measure
blood oxygenation without ambiguity caused by the change in
blood perfusion.38
From excitation fluence compensated PA measurements
at two or more wavelengths, the relative concentrations of
HbO2 and HbR can be quantified through spectral analysis,
and thus the absolute oxygen saturation of hemoglobin (sO2)
can be computed.21 By using OR-PAM with two-wavelength
measurements, Hu et al. quantified, for the first time, the
mouse brain microvascular oxygenation down to capillaries,
with the skull intact [Figs. 3(a) and 3(b)].16 This study has
opened a new window for neurovascular coupling research
through the measurement of neuroactivity-dependent changes
in hemoglobin concentration and oxygenation. Accurate excita-
tion fluence compensation is less problematic for OR-PAM
because of the superficial imaging depth. However, it is very
challenging for AR-PAM and PACT in the quasidiffusive and
diffusive regimes because of the wavelength-dependent light
attenuation in tissue.27
To circumvent the fluence compensation issue in AR-PAM,
Stein et al. reported a ratiometric method for relative oxygena-
tion measurement [Figs. 3(c) and 3(d)].39 In this method, the first
measurement at 570 nm is insensitive to oxygenation, and the
second measurement at 561 nm is HbR dominant. The pixelwise
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ratio between the two measurements reflects the local blood
oxygenation level, even though the local fluence is unknown.
Although the resultant functional image is not a quantitative
sO2 mapping, it is still useful when only the changes in
blood oxygenation are of interest. With this method, AR-
PAM was used to monitor mouse cortical oxygenation transition
between a hypoxic to a hyperoxic state. The dynamics of the
transitions were clearly observed with a detection sensitivity
of 3.6%. Interestingly, the results show that the brain vasculature
was much more resistant to transitioning from hyperoxia to
hypoxia than the other way around. Using a similar method,
Liao et al. studied mouse cortical oxygenation responses to elec-
trical stimulations to the forepaws on a single vessel basis.41,42
Alternatively, without fluence compensation, the acoustic
frequency spectra of PA signals at multiple optical wavelengths
can be used to calculate absolute concentrations of HbO2 and
HbR, and thus sO2.
43,44 Recently, another calibration-free
method for absolute sO2 quantification in PACT has been devel-
oped by Xia et al. based on the dynamics of the PA signals at
different oxygenation states [Figs. 3(e) and 3(f)].40 Briefly, at
each oxygenation state, multiwavelength PA measurements
are simultaneously performed, and the ratio of the PA measure-
ments between different oxygenation states cancels out the
effects of the heterogeneity of the laser fluence distribution
as long as the local fluence does not change during the oxygena-
tion transition. Therefore, absolute sO2 can be quantified with-
out the need to correct for the local fluence. With this method,
PACT was used to measure regional blood oxygenation in a
mouse brain while the mouse was challenged from hyperoxia
to hypoxia. Notably, the PACT measurement results also
showed that the transition from hyperoxia to hypoxia took a
longer time than the other way around, consistent with the
observations from AR-PAM.39
3.2 PAT of Brain Metabolism
Brain metabolism is another important indicator of brain activ-
ities. In humans, the brain consumes >20% of total energy, even
in the resting state, and most of this energy is used to sustain
neural activities.45 Since stronger neuron firing results in faster
consumption of glucose and oxygen, tracking the metabolic rate
of oxygen and glucose can provide valuable information about
brain activities. Besides neural activities, abnormal brain
metabolism may indicate diseases. In particular, hypermetabo-
lism is a hallmark of all kinds of brain cancers, where the cancer
cells are starving for oxygen and glucose.46 Since glucose can be
metabolized via either aerobic respiration or anaerobic respira-
tion, measurements of both glucose metabolism and oxygen
metabolism are needed to fully reflect the metabolic status of
brain tumors.
Positron emission tomography (PET) has been clinically
used for brain metabolism measurement by injection or inhala-
tion of radioactively labeled tracers. The detection sensitivity of
PET is on the level of pM. However, the complex procedure, low
resolution, high cost, and potential radiation exposure have lim-
ited its usage. On the other hand, PAT can measure the brain
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Fig. 3 Photoacoustic tomography (PAT) of mouse brain oxygenation. (a) OR-PAM of oxygen saturation
(sO2) in a mouse brain based on two-wavelength measurements at 570 and 578 nm.
16 (b) sO2 values in
percentage along an arterial tree and a venous tree marked by the dashed boxes in (a), showing
decreased sO2 with vessel branch orders. (c) AR-PAM of cortical vasculature in a living mouse.
39
The dotted white line indicates the line scanning range for oxygenation measurement. CS, coronal
suture. (d) Dynamic vessel responses acquired through a hypoxic challenge, shown in percent change
of ratiometric PA signals at 561 and 570 nm. Each colored trace corresponds to the respective cortical
vessel crossed by the dotted line in (c). (e) PACT of cortical vasculature in a living mouse.40
SSS, superior sagittal sinus. (f) Dynamics of absolute sO2 measured by PACT on the SSS in response
to a hypoxic challenge. The measured sO2 values based on the new oxygenation-state method are com-
pared with the conventional two-wavelength method. Adapted with permission from Refs. 16, 39, and 40.
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metabolism of both oxygen and glucose with a better resolution,
relatively low cost and less safety concern.47 Two examples
follow.
By using hemoglobin as an endogenous oxygen tracer, OR-
PAM is capable of studying oxygen metabolism in the brain.
Recently, by integrating fine spatial and temporal scales,
single-cell PA flowoxigraphy, a new implementation of OR-
PAM, is capable of imaging oxygen release from single RBCs
in vivo.48 As shown in Fig. 4, by fast line scanning (20 Hz) along
a capillary with two wavelength excitations, PA flowoxigraphy
can simultaneously measure multiple hemodynamic parameters
that are required to quantify the oxygen release rate by RBCs,
which is closely related to the local oxygen metabolism of neu-
ral cells. Experimental results show that PA flowoxigraphy can
be used to image the coupling between neural activity and oxy-
gen delivery in response to different physiological challenges,
such as visual stimulation and acute systematic hypoglycemia.
PA flowoxigraphy can be extremely useful in understanding
how the brain is powered at the single cell level.
Although glucose has been explored as an endogenous con-
trast agent for PAT measurement of blood sugar levels, the
detection sensitivity is still insufficient for clinical diagnosis,
mainly due to strong background absorption by water.49
Recently, a glucose analog, 2-NBDG, has been used to nonin-
vasively quantify glucose metabolism in a mouse brain. Similar
to the FDG used in PET, 2-NBDG is transported into cells by
glucose transporter GLUT. Inside cells, 2-NBDG is phosphat-
ized, but cannot be further metabolized. Therefore, the distribu-
tion of trapped 2-NBDG reflects the glucose uptake and thus the
local glucose metabolism. PACT with 2-NBDG was used for
noninvasive mouse brain metabolism studies,50 where the glu-
cose uptake rate in the somatosensory region was elevated by
∼3% in response to electrical stimulations to the mouse hind-
paws. 2-NBDG is suited for brain imaging because it can freely
pass blood–brain barrier (BBB) due to its relatively small mol-
ecule size. However, 2-NBDG has peak absorption at 480 nm.
Because of strong light attenuation by brain tissue at 480 nm,
2-NBDG is not ideal for deep brain imaging. In addition, it is
still under investigation whether most of the existing optical
glucose analogs share the same transport mechanism into the
brain as glucose.51 Alternatively, newly developed FRET-based
glucose sensors, especially genetically encoded fluorescent
proteins, can be expressed in the brain cells and do not need
transport across BBB, and thus can be adopted for PA imaging
of glucose metabolism in the future.52,53
3.3 PAT of Brain Resting-State Connectivity
The mammalian brain is subdivided into specialized regions for
various functions. These functional regions show pronounced
activities even in the resting state. The spatiotemporal correla-
tions between the spontaneous activities in different regions
stem from the anatomical connections and the underlying neural
activities in the brain cortex.54,55 fMRI and diffuse optical
tomography (DOT), the most commonly used functional brain
imaging tools for resting state studies, lack the spatial and/or
temporal resolution for small animal brain imaging.
Using the full-ring-array PACT system, Nasiriavanaki et al.
successfully imaged functional connectivity imaging in the
resting mouse brain, with an in-plane resolution of 100 μm
and a frame rate of 0.6 Hz (Fig. 5).56 The results clearly indicate
bilateral correlations between the main functional regions
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Fig. 4 Single cell label-free PA microscopy of oxygen metabolism
in vivo.48 (a) sO2 mapping of the brain vasculature. The yellow dashed
box indicates a capillary chosen for oxygen unloading measurement.
(b) Single cell oxygen unloading was measured by fast
line scanning along a capillary with two wavelength excitations.
Blood flows from left to right. The dashed arrow follows the trajectory
of a single flowing RBC. Scale bars: x ¼ 10 μm and z ¼ 30 μm.
Adapted with permission from Ref. 48.
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Fig. 5 Functional resting-state connectivity maps in a live mouse brain acquired noninvasively by
PACT.56 Correlation maps of (a) the main functional regions, (b) the four subregions of the somatosen-
sory cortex, and (c) the three subregions of the visual cortex. The white circles in the images are the seed
locations for the correlation calculation. Adapted with permission from Ref. 56.
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[Fig. 5(a)], as well as in several subregions [Figs. 5(b) and 5(c)].
The functional connectivity maps by PACT are automatically
coregistered with high-resolution cortical vascular images,
allowing pinpoint location of neural activities. Although not
demonstrated yet, by using spectral analysis, PACT can poten-
tially unmix the contributions of HbO2 and HbR to the func-
tional connectivity, which cannot be achieved by fMRI.
3.4 PAT of Brain Responses to Physiological
Challenges
In addition to resting state brain studies, PAT has also been
extensively used to image brain responses to various physiologi-
cal challenges in small animals, which may provide valuable
insights into the human brain. PAT can provide morphological,
functional, and metabolic imaging of the brain at different spa-
tiotemporal scales.
For example, brain responses to oxygenation challenges have
been imaged by PAT across the scales. Although the scalp was
removed for OR-PAM, both the scalp and skull were intact for
AR-PAM and PACT. Capitalizing on high spatial resolution,
OR-PAM is able to scrutinize the oxygenation transitions in sin-
gle capillaries or even in single RBCs; however, the imaging
depth is limited to <1 mm.48 AR-PAM can image brain oxy-
genation transitions at depths up to a few millimeters, but
only cross-sectional images can be repeatedly acquired, limited
by its temporal resolution.39 In contrast, full-ring PACT can
image the oxygenation transitions over the entire mouse brain
cortex at a high imaging speed, but with compromised spatial
resolution.40
Small animal brain responses to other physiological chal-
lenges have also been imaged by PAT, including applying
electrical stimulations to paws [Fig. 6(a)],41,50 vibrational stim-
ulations to whiskers [Fig. 6(b)],18 optical stimulations to eyes
[Fig. 6(c)],48 direct electrical stimulations to brains,57 and injec-
tion of cocaine hydrochloride.58
3.5 PAT of Small Animal Models for
Brain Disorders
Over the years, many small animal models have been developed
for studying human brain diseases, including brain tumors,
stroke, epilepsy, traumatic brain injury, Parkinson’s disease,
Huntington’s disease, and Alzheimer’s disease.3 By combining
appropriate imaging techniques with suitable small animal
models, it has become possible to investigate the underlying
mechanisms of brain diseases in a controlled manner and on
a much finer scale than is possible in humans.59,60
So far, PAT has been applied in studies of a number of brain
disease models. Li et al. were the first to apply functional PACT
to image a human glioblastoma at ∼3-mm depth in mouse brains
[Fig. 7(a)].61 The increased total hemoglobin concentration in
the tumor region indicated tumor angiogenesis, and the
decreased oxygen saturation suggested a hypoxic tumor vascu-
lature: both are hallmarks of late-stage cancers. Staley et al. were
the first to demonstrate noninvasive longitudinal monitoring of
melanoma growth and metastasis in a mouse brain by using
PAMac.62 The strong absorption of melanin provided an excel-
lent signal-to-noise ratio of ∼30 dB, with the tumor implanted
∼3 mm beneath the skull.
Xu et al. were the first to apply PACT to study mouse
cerebral edema induced by cold injury [Fig. 7(b)]. In this
study, the formation, expansion, and recovery of edema were
noninvasively monitored by PACT, where water content in
the edema provided PA image contrast at 975 nm.63
Significantly, this study demonstrated the potential of in vivo
water imaging by PAT. Hu et al. were the first to apply OR-
PAM to longitudinally study ischemic stroke induced brain
injury in a mouse model [Fig. 7(c)].64 The focal brain ischemia
was caused by 1-h transient middle cerebral artery occlusion
(MCAO). A significant drop in sO2 was observed in the core
stroke region right after MCAO, which eventually led to
brain infarction after 24 days.
Zhang et al. and Tsytsarev et al. explored noninvasive or min-
imally invasive imaging of drug-induced epileptic seizures in
animal models using PACT (Ref. 65) and OR-PAM (Ref. 66),
respectively. With PACT’s wide field of view, it was found that
the seizures induced an increase in the PA signal confined in
the epileptic core region. However, limited by the spatial reso-
lution of PACT, it was unknown whether the increase in PA
signal was caused by an increase in vessel diameters, total
hemoglobin concentration, or both. This question was later
resolved in a study with OR-PAM, where an artery–vein pair
- +
Stimulator
(a)
(b)
2 mm
4 mm
Left Right
Left Right
(c) Stimulation
||∇sO2||
vf
rO2
Fig. 6 PAT of brain hemodynamics in responses to stimulations.
(a) PACT of mouse brain hemodynamics in response to electrical
stimulations on the hindpaws showing the elevated blood perfusion
in the contralateral somatosensory regions.50 The PA signal increases
(in color) are superimposed on the vascular image (in gray). (b) PACT
of rat brain hemodynamics in response to vibrational stimulations on
the whiskers, showing the increased blood perfusion in the contralat-
eral somatosensory region.18 The PA signal increases (in red color)
are superimposed on the vascular image (in gray). (c) OR-PAM of
neuron-RBC coupling in the mouse visual cortex.48 The eye of a
mouse was stimulated by a flashing LED (left), and transient
responses to a single visual stimulation were monitored. Clear
increases were observed in the magnitude of the sO2 gradient
(jj∇sO2jj), blood flow speed (vf) and oxygen unloading rate (rO2).
Adapted with permission from Refs. 18, 48, and 50.
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was imaged.66 The seizures induced simultaneous increases in
the vessel diameters and total hemoglobin concentrations in
both the artery and the vein. Compared with the vein, the
increase in the artery had a reduced amplitude but a prolonged
time. The cross-validation of the epileptic observations at differ-
ent length scales is a good example of the powerful multiscale
imaging capability of PAT in brain research.
Another disease model, norepinephrine induced brain hyper-
tension, was studied by Liu et al. with OR-PAM.67 By virtue of
the high spatiotemporal resolution and multiparametric imaging
capability of OR-PAM, for the first time, the effects of norepi-
nephrine on the brain hemodynamics were investigated on
a single vessel level. The key findings showed clear causal
consequences following the drug administration: severe vessel
constriction resulted in reduced blood perfusion, which was
followed by a drop in oxygen saturation.
Many other small animal models have been used for PA brain
imaging.68–70 Collectively, these small animal disease models
have demonstrated the great potential of PAT for monitoring
the brain’s physiological and pathological status, and in assess-
ing the effects of treatments.
4 PA Molecular Imaging in the Brain
In mammals, the brain is largely composed of water (w/w 78%),
lipids (12%), proteins (8%), and other substances (2%).71
Compared with other internal organs, the brain has a relatively
high content of lipids. Particularly, the dry mass of myelin is
70% to 85% lipids. Hemoglobin is about 1.5% of the total
brain mass.71 All these endogenous components can be imaged
by PAT at their absorption wavelengths. So far, hemoglobin is
most widely used in PA hemodynamic imaging of brain.8 As
discussed above, water has also been explored in PAT of
brain edema.72 Lipids in myelin have been imaged in peripheral
nerves20 and can be potentially used for imaging the central
nervous system.
In addition to these endogenous contrasts, PAT can utilize
exogenous contrasts for molecular brain imaging with enhanced
specificity and sensitivity. Molecular imaging enables visualiz-
ing the cellular function and the molecular processes. PA
molecular imaging differs from traditional PA imaging, in
that targeting molecules (e.g., antibodies) are conjugated to
the imaging probes and used to help image particular targets
or pathways. In recent years, great efforts have been devoted
to promote the molecular imaging capability of PAT, and con-
siderable progress has been made in optimizing both the PAT
imaging systems for better detection sensitivity,73–75 signal
processing methods for better spectral unmixing,43,44,76 and
the contrast agents for better contrast enhancement.77–80
Notably, a new technology referred to as multispectral opto-
acoustic tomography has been actively used for PA molecular
imaging.80,81 PAT has proven capable of high sensitivity
molecular imaging by using various exogenous contrast agents,
including nanoparticles, organic dyes, fluorescent proteins, and
reporter gene products.82
However, unlike other organs, the brain presents a significant
obstacle for molecular imaging: the BBB.83,84 The BBB protects
the brain from noxious agents; however, it also significantly hin-
ders the delivery of contrast agents to the brain. Through the
tight junctions between capillary endothelial cells, the BBB
blocks the diffusion of nearly 100% of microscopic objects
(e.g., bacteria) and >95% of large or hydrophilic molecules
into the cerebrospinal fluid (CSF).85 For ideal brain molecular
imaging, the exogenous contrast agents need to cross the BBB in
adequate quantity and remain in the brain for a sufficient time.
So far, various methods have been used to break, bypass or
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Fig. 7 Noninvasive PAT of small animal disease models. (a) Functional PACT of a glioblastoma in a
mouse brain showing the hypoxic tumor region (left).61 The tumor region was confirmed by a postmortem
photograph of the excised mouse brain (right). (b) PACT of cold-injury induced edema in a mouse brain,
where the water content provided the image contrast at 975 nm (left).63 The edema region was confirmed
by the MRI T2 image. (c) Longitudinal transcranial OR-PAM monitoring of cerebral sO2 during stroke-
induced brain damage.64 The stroke was induced by 1-h transient middle cerebral artery occlusion
(MCAO). sO2 images were acquired before, during, right after, and 24 days after the MCAO. MCA, middle
cerebral artery. Adapted with permission from Refs. 61, 63, and 64.
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“trick” the BBB in order to deliver contrast agents into the
brain.83 These include physically or chemically opening the
BBB, direct delivery into the CSF, and active transport by intrin-
sic carriers.
Due to the relatively small molecule size (<10 nm), organic
dyes may be delivered through the BBB by active transport. As
discussed, 2-NBDG, a glucose analog, can be transported across
the BBB via glucose transport protein GLUT [Fig. 8(a)].86,87
The active transport is safe for the barrier, and the passage is
well regulated by the available transport carriers. The disadvant-
age is that only a small number of organic dyes can be trans-
ported.88 For example, another glucose analog, IRDye800-DG,
may not be actively transported due to its large molecule size.89
In addition to active transport, the BBB can also be chemi-
cally or physically opened to allow the free diffusion of contrast
agents.91 Li et al. used IRDye800-c(KRGDf) to target the
overexpressed integrin αvβ3 in brain glioblastoma.
61 Before
the administration of IRDye800-c(KRGDf), the mouse brain
BBB was opened by intravenous injection of mannitol, which
could temporarily shrink the endothelial cells and simultane-
ously stretch the tight junctions between them [Fig. 8(b)].92 PAT
achieved a detection sensitivity of ∼250 nM of IRDye800-c
(KRGDf), with an incident laser fluence of 20 mJ∕cm2 at
784 nm. However, the drawbacks of forcibly opening the
BBB include potential damage to the barrier as well as uncon-
trolled passage of contrast agents into the brain.
Compared with organic dyes, nanoparticles are relatively
large (>10 nm) and thus more difficult to transport across
the BBB.84 However, nanoparticles can be more easily engi-
neered for PA molecular imaging; in particular, the peak
absorption wavelength can be easily tuned.78,79,93,94 Numerous
nanoparticles with various sizes, shapes, and compositions
have been used for PA molecular imaging, especially in vascular
enhancement,95,96 early cancer detection,97–99 drug deliv-
ery,100,101 and sentinel lymph node mapping.102,103 However,
only a few of them have been explored for PAT of the brain,
mostly due to the difficulty of passing the BBB.
Nevertheless, in recent years, different methods have been
studied for controlled nanoparticles delivery to the brain.83
Kircher et al. developed a brain tumor molecular imaging
method using triple-modality MRI-photoacoustic-Raman nano-
particles.90 In this method, gold-silica-based nanoparticles
coated with Gd3þ ions enhanced PA imaging of glioblastoma
in a mouse brain with an intact scalp and skull. Here, the nano-
particles diffused through the disrupted BBB and accumulated
in tumor cells without the need for a specific targeting
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Fig. 8 PA molecular imaging of the mouse brain. (a) PACT of glucose metabolism in a mouse brain, by
using 2-NBDG as the contrast agent.50 2-NBDG was delivered across the blood–brain barrier (BBB) via
active transport by glucose transport protein GLUT. (b) PACT of a glioblastoma in a mouse brain
enhanced by IRDye800-c(KRGDf), which targeted the overexpressed integrin αvβ3 in tumor cells.
18
The BBB was forcibly opened by intravenous injection of mannitol, which temporarily shrank the endo-
thelial cells and simultaneously stretched the tight junctions of the BBB. (c) PAMac of a glioblastoma in a
mouse brain enhanced by trimodality MRI-photoacoustic-Raman nanoparticles.90 Here, the nanopar-
ticles diffused through the disrupted BBB and accumulated in tumor cells without the need for a specific
targeting mechanism, a phenomenon referred to as the enhanced permeability and retention (EPR)
effect. Adapted with permission from Refs. 50, 61, and 90.
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mechanism, a phenomenon referred to as the enhanced per-
meability and retention (EPR) effect [Fig. 8(c)].90,104 A PA
detection sensitivity of 50 pM was achieved with an incident
laser energy of 8 mJ∕cm2. However, the EPR effect is consid-
ered a widely variable phenomenon that highly depends on the
local tumor environment and cannot be relied on for robust
delivery of nanoparticles across the BBB.83
Compared with organic dyes and nanoparticles, reporter
gene products have a significant advantage for brain imaging:
the gene products are expressed in living brain cells and do
not need complex exogenous delivery across the BBB. So
far, various fluorescent genetically encoded proteins have
been explored for PA molecular imaging, such as mCherry,
EGFP, iRFP, and RFP.105–109 Li et al. reported the first PA
reporter gene imaging in rat brains, where gliosarcoma cells
expressing LacZ gene were imaged by PACT using the blue
product as the contrast agent.110 The blue product was produced
from LacZ encoded β-galactosidase and locally injected X-gal.
A detection sensitivity of 500 nM was demonstrated with an
incident laser fluence of 5 mJ∕cm2. A drawback of LacZ
gene imaging is that X-gal needs to be injected locally,
which may cause brain damage. Recently, using multispectral
PAT, Razansky et al. demonstrated PAT of mCherry in the
brain of an adult (6-month-old) transgenic zebrafish, where
no extra imaging substances were needed.105
However, compared with organic dyes, most fluorescent
proteins have relatively low extinction coefficients and low
photostability, and thus are not ideally suited as PA genetic
reporters.106 To resolve this issue, given the strong optical
absorption of melanin, a few groups have been working on
transferring tyrosinase genes to nonmelanogenic cells to encode
eumelanin as the contrast agent for PA imaging. However, the
melanin synthesis usually consumes considerable cellular
resources and may jeopardize normal cell functions.111–114
5 Challenges for PAT of the Human Brain
Clinical translation of PAT to human brain imaging is one of its
most exciting directions. With better resolution than that of
fMRI and richer functional information than that of ultrasound,
PAT is expected to become a powerful tool for understanding
various neural activities and cognitive phenomena. However,
despite the successes in small animal brain imaging, PAT of
the human brain still faces challenges. The major obstacle is
that the incident light and the emitted ultrasound need to go
through the thick human skull (∼7 to 11 mm for adolescents
and adults), which is much thicker than a mouse skull (∼0.2
to 0.3 mm), a rat skull (∼0.7 to 1 mm), or a monkey skull
(∼2 to 4 mm). The skull can strongly absorb and scatter
light, and attenuate and distort ultrasound as well.
The strong optical attenuation of the skull is largely due to its
high optical scattering.115 The reduced scattering coefficient of
human skull in NIR region is ∼1.3 to 2.7 mm−1. The direct
light transmittance at 1064 nm through the top of the fixed
human skull is only ∼2.1%.116 Since the American National
Standards Institute safety standard requires the incident light
fluence at the skull surface to be <100 mJ∕cm2 in the NIR
region, the maximum delivered fluence at the brain surface is
about 2 mJ∕cm2.
The detection phase suffers strong acoustic attenuation of the
skull (∼20 dB∕cm at 1 MHz), which is about 25 times that of
brain tissue (0.8 dB∕cm).117,118 In addition to degrading the
SNR, the skull also introduces severe acoustic signal aberration
associated with acoustic wave reflection and refraction within
the skull.119 The acoustic aberration is due to the acoustic
impedance mismatch between the skull (∼7.7 × 106 Rayls)
and the brain (∼1.6 × 106 Rayls),117 and the distorted acoustic
waves can significantly deteriorate the reconstructed image
quality.
Although the above challenges have hindered the progress in
PAT of the human brain, concerted efforts have been made to
improve the image quality. To optimize the incident light deliv-
ery, Nie et al. have developed a novel photon cycler for PACT to
recycle photons back-scatted by the skull. The recycler is coated
with titanium white pigment and can effectively reflect the pho-
tons back to the brain to generate PA signals.116 An ex vivo
experiment with a canine brain covered by a human skull
showed that the photon recycler improved the SNR by 2.4 times.
Furthermore, due to the relatively low optical absorption of
the skull in the NIR region, NIR contrast agents can be used
to improve the SNR. Wang et al. used polyethylene glycol
conjugated indocyanine green (ICG), which absorbs strongly
at 790 nm, to enhance hemodynamic imaging in the rat brain
with intact scalp and skull.120 A detection sensitivity of 10 μM
was demonstrated with an incident laser fluence of 2 mJ∕cm2.
Since ICG is an FDA approved contrast agent for determining
human cardiac output,121 it may also be used for human brain
imaging.
Because the high frequency signal is attenuated faster than
the low frequency signal, much of the PA signal emitted through
a human skull resides at frequencies lower than 1 MHz.
Therefore, an ultrasonic detection system that matches the PA
signal bandwidth can further improve the SNR.118,119
In addition to the engineering improvements to PAT systems,
image reconstruction methods have also been improved to cor-
rect for the acoustic signal distortions. Huang et al. have used
adjunct X-ray CT data of a skull to extract speed of sound (SOS)
and mass density, from which the acoustic impedance of the
skull can be calculated.119 Their phantom experiments showed
that, by incorporating these quantities into the time-reversal
image reconstruction, skull-introduced signal aberrations were
corrected, and thus the reconstructed image artifacts were
reduced. Similarly, Xia et al. have incorporated ultrasonic com-
puted tomography with PACT to correct for SOS heterogeneity
within the field of view, which can substantially improve the
image quality especially for large targets.122
6 Conclusions and Outlook
Brain mapping will not just unlock the mystery of how the brain
works, but also create a platform for better diagnostics and
therapeutics of brain disorders.3 Although many technologies
have been used for brain imaging, there is still a large role
for PAT to play, complementing other modalities. Particularly,
the high scalability of PATwill enable high resolution brain im-
aging at length scales ranging from single neurons to individual
functional regions, using the same optical absorption contrast.
The functional imaging capability of PAT will help to address
how the brain operates in normal conditions and why it falls
into disorders.
As a maturing technology, PAT has not yet realized its utmost
potentials in brain imaging. For small animal brain imaging,
PAT of awake animals will open a new door to many investiga-
tions that can bridge the gap between neural activity and behav-
ior. Further miniaturizing PAT systems with microfabrication
technologies may allow mounting the imaging system on the
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animal’s head without jeopardizing the animal’s normal activ-
ity.123,124 Alternatively, head restraint may be possible using a
standard PAT system. For example, an air-supported spherical
treadmill may be adapted for PAT of awake mice.125
Moreover, direct neural activities in vivo can be photoacousti-
cally detected by using voltage-sensitive dyes or calcium-sensi-
tive dyes, whose fluorescence emission changes when a neuron
fires an action potential.105,126
Human brain imaging will remain as one of the most impor-
tant tasks of PAT, and is expecting breakthroughs in the coming
years. Novel light delivery methods are needed to improve the
illumination efficiency. To bypass skull attenuation, the nose,
ear, and mouth cavities may be used to deliver light to the
deep brain. In contrast to adult brain, neonatal brain PAT should
be much less challenging due to the thinner skull and the soft
fontanel. Novel reconstruction methods assisted by X-ray CT or
MRI can correct for the acoustic signal distortions by the skull.
More PAT contrast agents with strong optical absorption and
high biocompatibility will be developed to specifically target
the brain. New methods for delivering the contrast agents
through the BBB will be explored, for example, by direct deliv-
ery through the nasal cavity. Eventually, building on advances in
imaging systems, reconstruction methods and contrast agents,
functional human brain imaging by PAT will become highly
possible.
In conclusion, considering its highly scalable spatial resolu-
tion, imaging speed, penetration depth, and functionality, we
expect that PAT will become a promising tool for fundamental
neurophysiological studies and clinical neurological practice.
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